{
  "ticker": "AUK",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02972252",
  "id": "02972252",
  "pages": 2,
  "price_sensitive": true,
  "date": "20250724",
  "time": "0936",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250724/pdf/06m33k0mygwsqk.pdf",
  "summary": "- **Revenue Growth**: FY25 unaudited revenue expected to exceed AUD 39m, up >50% from AUD 25.87m in FY24.  \n- **Strategic Shift**: Transitioning to lower-cost models, expanding into China Hospital Pharmacies, and launching own-branded products (e.g., BioBasics) in China/USA via partnerships.  \n- **Corporate Restructuring**: Simplified into two business units to reduce costs, improve clarity on profitability, and focus on brand incubation/acquisition.  \n\n*Omitted: Forward-looking statements, operational details, chairman commentary.*",
  "usage": {
    "prompt_tokens": 1146,
    "completion_tokens": 120,
    "total_tokens": 1266,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-23T23:43:37.017313"
}